tanzisertib
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2011 (NCT01203943)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- c-Jun N-terminal kinase 1INHIBITOR
MAPK8 inhibitor
- c-Jun N-terminal kinase 3INHIBITOR
MAPK10 inhibitor
- c-Jun N-terminal kinase 2INHIBITOR
MAPK9 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1- Mol. weight
- 448.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1950289 ↗
Also known as
- (141c)tanzisertib
- 4-(9-(tetrahydrofuran-3-yl))-8-(2,4,6-trifluorophenylamino)-9h-purin-2-ylaminocyclohexan-1-ol
- 4-(9-(tetrahydrofuran-3-yl)-8-(2,4,6-trifluorophenylamino)-9h-purin-2-ylamino)cyclohexanol
- cc-930
- cc-930
- cc-930
- cc-930
- jnk-930
- jnk-930
- tanzisertib
- tanzisertib
- tanzisertib
- tanzisertib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01466725 | Phase 2 | Nov 1, 2011 | Celgene |
| NCT01203943 | Phase 2 | Jan 1, 2011 | Celgene |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celgene | For profit | 2 | 2 | 1 | 2011 |
1 organizations
Page 1 / 1